pyrroles has been researched along with Cancer of Testis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, AM; Meric-Bernstam, F; Mills, GB; Pagliaro, LC; Rao, P; Shaw, KR; Subbiah, V; Ward, JF | 1 |
| Aigner, F; Heidegger, I; Horninger, W; Pichler, R; Tulchiner, G | 1 |
| Capellà, G; Casanovas, O; Castillo-Avila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Mora, J; Piulats, JM; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Ishill, N; Motzer, RJ; Patil, S; Turkula, S | 1 |
| Bokemeyer, C; Cheng, T; Chi, K; Czaykowski, P; Fenner, M; Glaesener, S; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Winquist, E; Wood, L | 1 |
| Bajorin, DF; Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Motzer, RJ; Patil, S; Sheinfeld, J; Trinos, MJ | 1 |
3 trial(s) available for pyrroles and Cancer of Testis
| Article | Year |
|---|---|
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Platinum Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrroles; Retroperitoneal Neoplasms; Sunitinib; Testicular Neoplasms; Young Adult | 2014 |
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Secondary Prevention; Sunitinib; Testicular Neoplasms | 2010 |
Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease-Free Survival; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Sunitinib; Testicular Neoplasms; Treatment Outcome; Young Adult | 2011 |
3 other study(ies) available for pyrroles and Cancer of Testis
| Article | Year |
|---|---|
Paratesticular Metastasis of a Clear-Cell Renal-Cell Carcinoma With Renal Vein Thrombus Mimicking Primary Testicular Cancer.
Topics: Carcinoma, Renal Cell; Diagnosis, Differential; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Orchiectomy; Pyrroles; Sunitinib; Testicular Neoplasms; Thrombectomy; Treatment Outcome; Venous Thrombosis | 2017 |
Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Germ Cell and Embryonal; Neovascularization, Pathologic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Survival Analysis; Testicular Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Endpoint Determination; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Retroperitoneal Neoplasms; Retrospective Studies; Sunitinib; Suramin; Testicular Neoplasms; Topotecan; Treatment Outcome; Young Adult | 2012 |